Serum Uric Acid in Adolescents With Primary Headache: A Case-Control Study (NCT07460830) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Serum Uric Acid in Adolescents With Primary Headache: A Case-Control Study
80 participantsStarted 2026-03-15
Plain-language summary
This observational, case-control study will evaluate differences in serum uric acid and related hematologic and biochemical parameters between adolescents (12-18 years) with primary headache and age-/sex-matched controls without recurrent headaches or chronic medical/psychiatric disorders. Cases will meet International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria verified by a pediatric neurologist after comprehensive clinical assessment. The study will also collect sociodemographic data and anthropometrics to calculate BMI. Primary outcome is the between-group difference in serum uric acid levels at enrollment. Secondary outcomes include group differences in ferritin, creatinine, BUN, complete blood count indices (Hb, WBC, neutrophils, lymphocytes, platelets, MPV), and BMI.
Who can participate
Age range12 Years – 18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Inclusion Criteria (Cases):
Adolescents aged 12-18 years presenting to pediatric neurology outpatient clinics
Diagnosis of primary headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) (e.g., 1.1, 1.2, etc.)
Diagnosis confirmed by a pediatric neurologist following a comprehensive clinical evaluation
Sufficient cognitive ability to understand and complete study instruments
* Inclusion Criteria (Controls):
Adolescents aged 12-18 years presenting to general pediatric outpatient clinics
No history of recurrent headaches
No chronic medical or psychiatric disorders
Matched with the case group for age and sex
Exclusion Criteria:
* History of neurological disorders other than primary headache
* Previously diagnosed psychiatric conditions
* Autoimmune diseases, chronic infections, severe cardiac failure, metabolic or inflammatory disorders, obesity, or significant hepatic or renal impairment
* Regular use of psychotropic medications or a history of polycythemia
* Use of drugs known to affect uric acid metabolism within 2-4 weeks prior to enrollment
* Cognitive or developmental disabilities limiting the ability to understand or complete study instruments